HomeCompareVIAP vs KO

VIAP vs KO: Dividend Comparison 2026

VIAP yields 400000.00% · KO yields 2.71%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 VIAP wins by $5.011119029548644e+32M in total portfolio value
10 years
VIAP
VIAP
● Live price
400000.00%
Share price
$0.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$5.011119029548644e+32M
Annual income
$500,865,583,351,836,840,000,000,000,000,000,000,000.00
Full VIAP calculator →
KO
The Coca-Cola Company
● Live price
2.71%
Share price
$76.05
Annual div
$2.06
5Y div CAGR
24.3%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$34.1K
Annual income
$4,323.37
Full KO calculator →

Portfolio growth — VIAP vs KO

📍 VIAP pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodVIAPKO
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, VIAP + KO cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
VIAP pays
KO pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

VIAP
Annual income on $10K today (after 15% tax)
$34,000,000.00/yr
After 10yr DRIP, annual income (after tax)
$425,735,745,849,061,300,000,000,000,000,000,000,000.00/yr
KO
Annual income on $10K today (after 15% tax)
$230.24/yr
After 10yr DRIP, annual income (after tax)
$3,674.86/yr
At 15% tax rate, VIAP beats the other by $425,735,745,849,061,300,000,000,000,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of VIAP + KO for your $10,000?

VIAP: 50%KO: 50%
100% KO50/50100% VIAP
Portfolio after 10yr
$2.505559514774322e+32M
Annual income
$250,432,791,675,918,420,000,000,000,000,000,000,000.00/yr
Blended yield
99.95%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on KO right now

VIAP
No analyst data
Altman Z
-338.9
Piotroski
1/9
KO
Analyst Ratings
29
Buy
16
Hold
3
Sell
Consensus: Buy
Price Target
$84.88
+11.6% upside vs current
Range: $81.00 — $88.00
Altman Z
5.0
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

VIAP buys
0
KO buys
13
PoliticianChamberTickerTypeAmountDate
Markwayne Mullin🏛 Senate$KO▲ Buy$15,001 - $50,0002025-12-29
Markwayne Mullin🏛 Senate$KO▲ Buy$15,001 - $50,0002025-12-29
Lloyd Doggett🏢 House$KO▲ Buy$1,001 - $15,0002025-12-15
Sheldon Whitehouse🏛 Senate$KO▲ Buy$1,001 - $15,0002025-11-21
Sheldon Whitehouse🏛 Senate$KO▲ Buy$1,001 - $15,0002025-11-21
Julia Letlow🏢 House$KO▲ Buy$1,001 - $15,0002025-11-03
Lisa McClain🏢 House$KO▲ Buy$1,001 - $15,0002025-09-25
Lisa McClain🏢 House$KO▲ Buy$1,001 - $15,0002025-09-25
Val Hoyle🏢 House$KO▼ Sell$1,001 - $15,0002025-09-23
Ro Khanna🏢 House$KO▼ Sell$1,001 - $15,0002025-09-05
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricVIAPKO
Forward yield400000.00%2.71%
Annual dividend / share$2.00$2.06
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%24.3%
Portfolio after 10y$5.011119029548644e+32M$34.1K
Annual income after 10y$500,865,583,351,836,840,000,000,000,000,000,000,000.00$4,323.37
Total dividends collected$5.010957816668433e+32M$15.6K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples

Year-by-year: VIAP vs KO ($10,000, DRIP)

YearVIAP PortfolioVIAP Income/yrKO PortfolioKO Income/yrGap
1← crossover$40,010,700$40,000,000.00$10,847$336.70+$40.00MVIAP
2$149,615,521,729$149,572,710,280.37$11,832$431.92+$149615.51MVIAP
3$522,880,052,725,200$522,719,964,116,949.25$12,992$557.22+$522880052.71MVIAP
4$1,707,862,989,289,045,000$1,707,303,507,632,628,700.00$14,379$723.66+$1707862989289.03MVIAP
5$5,213,509,402,845,684,000,000$5,211,681,989,447,144,000,000.00$16,059$947.18+$5213509402845684.00MVIAP
6$14,874,219,058,409,543,000,000,000$14,868,640,603,348,497,000,000,000.00$18,129$1,251.14+$14874219058409543680.00MVIAP
7$39,661,196,234,050,755,000,000,000,000$39,645,280,819,658,260,000,000,000,000.00$20,724$1,670.45+$3.966119623405075e+22MVIAP
8$98,838,436,350,327,300,000,000,000,000,000$98,795,998,870,356,880,000,000,000,000,000.00$24,040$2,258.40+$9.88384363503273e+25MVIAP
9$230,205,236,474,344,900,000,000,000,000,000,000$230,099,479,347,450,050,000,000,000,000,000,000.00$28,364$3,098.25+$2.302052364743449e+29MVIAP
10$501,111,902,954,864,400,000,000,000,000,000,000,000$500,865,583,351,836,840,000,000,000,000,000,000,000.00$34,134$4,323.37+$5.011119029548644e+32MVIAP

VIAP vs KO: Complete Analysis 2026

VIAPStock

VIA Pharmaceuticals, Inc., a development stage biotechnology company, focuses on the development of compounds for the treatment of cardiovascular and metabolic diseases. It is developing a pipeline of small molecule drugs that target the underlying causes of cardiovascular and metabolic diseases, including vascular inflammation, high cholesterol, high triglycerides, and insulin sensitization/diabetes. The company's drug development pipeline includes VIA-3196, a Phase-1 ready liver-directed thyroid hormone receptor (THR) beta agonist that targets dyslipidemia, such as high LDL cholesterol, high triglycerides, and elevated Lp(a); Diacylglycerol Acyl Transferase 1 (DGAT1) inhibitor, which is in pre-clinical development stage treatment of type 2 diabetes with upside potential in weight control and dyslipidemia; and VIA-2291, a 5-Lipoxygenase inhibitor that has completed third Phase 2 clinical trial for the treatment of atherosclerotic plaque, an underlying cause of heart attack, stroke, and other vascular diseases. VIA Pharmaceuticals, Inc. has two research, development, and commercialization agreements with Hoffman-LaRoche Inc. and Hoffman-LaRoche Ltd. for THR beta agonist; and multiple compounds from preclinical DGAT1 metabolic disorders program. The company was founded in 2004 and is headquartered in San Francisco, California.

Full VIAP Calculator →

KOConsumer Staples

The Coca-Cola Company, a beverage company, manufactures, markets, and sells various nonalcoholic beverages worldwide. The company provides sparkling soft drinks, sparkling flavors; water, sports, coffee, and tea; juice, value-added dairy, and plant-based beverages; and other beverages. It also offers beverage concentrates and syrups, as well as fountain syrups to fountain retailers, such as restaurants and convenience stores. The company sells its products under the Coca-Cola, Diet Coke/Coca-Cola Light, Coca-Cola Zero Sugar, caffeine free Diet Coke, Cherry Coke, Fanta Orange, Fanta Zero Orange, Fanta Zero Sugar, Fanta Apple, Sprite, Sprite Zero Sugar, Simply Orange, Simply Apple, Simply Grapefruit, Fresca, Schweppes, Thums Up, Aquarius, Ayataka, BODYARMOR, Ciel, Costa, Dasani, dogadan, FUZE TEA, Georgia, glacéau smartwater, glacéau vitaminwater, Gold Peak, Ice Dew, I LOHAS, Powerade, Topo Chico, AdeS, Del Valle, fairlife, innocent, Minute Maid, and Minute Maid Pulpy brands. It operates through a network of independent bottling partners, distributors, wholesalers, and retailers, as well as through bottling and distribution operators. The company was founded in 1886 and is headquartered in Atlanta, Georgia.

Full KO Calculator →
📬

Get this VIAP vs KO comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

VIAP vs SCHDVIAP vs JEPIVIAP vs OVIAP vs MAINVIAP vs PEPVIAP vs PGVIAP vs JNJVIAP vs MCD

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.